Genetic ablation of bioL led to biotin auxotrophy in Elizabethkingia, suggesting balanced BioE expression is critical for targeting drug-resistant pathogens.
Biotin is an essential cofactor for central metabolic pathways in all organisms. The newly identified BioE‐BioL module constitutes a new biotin biosynthesis pathway, yet its mechanisms remain incompletely characterized. Phylogenetic analyses reveal widespread distribution of the bioE , including obligate intracellular Chlamydia , despite the genus lacking its cognate repressor BioL. Structural modeling and biochemical characterization of Elizabethkingia meningoseptica BioE (EmBioE) and Chlamydia psittaci BioE (CpBioE) reveal a conserved diiron oxygenase catalytic core but divergent oligomeric structure state and substrate preferences. EmBioE forms a homodimer capable of recognizing both long‐chain acyl‐ACP and acyl‐CoA, whereas CpBioE functions as a monomer restricted to acyl‐ACP. Heterologous overexpression of EmBioE, but not CpBioE, induces a fitness cost in Escherichia coli . Genetic ablation of bioL leads to biotin auxotrophy in Elizabethkingia , mainly attributed to the unregulated EmBioE pathway exhausting long‐chain fatty acids and depleting ATP/SAM metabolic pools. This highlights EmBioE's biphasic role: initiating biotin synthesis to sustain viability while inducing stress upon overexpression, requiring BioL regulation for metabolic homeostasis. Virtual screening uncovers compound 466982 as a selective BioE inhibitor with dose‐dependent antibacterial activity against Elizabethkingia . Balanced BioE expression is critical for bacterial viability, positioning BioE as a druggable target for antimicrobial discovery against multidrug‐resistant pathogens.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: